Wednesday, February 10, 2010, 2:10PM AEST - The Australian Stockmarket closes in 1 hour and 55 minutes.
To create a watchlist or portfolio of shares, Register

Pain Therapeutics Inc. (PTIE)

8:00AM AEST: 5.56 USD  Up 0.11 (2.02%)  
 MORE ON PTIE 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Pain Therapeutics (NasdaqNM:PTIE) Delayed quote dataEdit
Last Trade:5.56 USD
Trade Time: 8:00AM AEST
Change:Up 0.11 (2.02%)
Prev Close:5.45
Open:5.48
Bid:5.00 x 100
Ask:5.90 x 1800
1y Target Est:5.00
Day's Range:5.48 - 5.59
52wk Range:3.20 - 6.26
Volume:113,051
Avg Vol (3m):207,941
Market Cap:235.18M
P/E (ttm):N/A
EPS (ttm):-0.11
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add PTIE to Portfolio   Download Data

 HEADLINES 
PAIN THERAPEUTICS INC Financials
EDGAR Online Financials (Sat, Feb 6)
PAIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights
EDGAR Online (Wed, Feb 3)
PAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report
EDGAR Online (Tue, Feb 2)
New Star Analyst Rankings for Pain Therapeutics
StarMine (Sun, Jan 31)
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Fri, Jan 29)
Pain Therapeutics Announces 2009 Financial Results, Outlines Business Priorities
GlobeNewswire (Fri, Jan 29)
PAIN THERAPEUTICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Material Modification to Ri
EDGAR Online (Wed, Jan 27)
PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Jan 8)
5 Stocks Bouncing Back
at Motley Fool (Sat, Dec 12)
Today's 5-Star Movers
at Motley Fool (Sat, Dec 5)
More Headlines for PTIE...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.11
EPS Est (in 2 years) (Dec-10) :-0.26
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxyco...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices